Search Clinical Trials

REFINE SEARCH
20  Results   |    Clear Filters

Age group

Category

Primary purpose

Study type

Location

Principal investigator

Search results

Displaying 1 - 20 of 20

Open Actively Recruiting

COVID-19 Outcome Prediction Algorithm

Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.

Gender: All
Age Group: Adults
Contact: GALYNA BONDAR
Investigator: Mario C. Deng, MD
Open Actively Recruiting

Study of Obeldesivir in Children and Adolescents With COVID-19

The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).

The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.

Phase: Phase 2/Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Michele Carter
Open Actively Recruiting

The Effect of the COVID-19 Pandemic on Glaucoma Care

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults, Children
Contact: Margarita Gonzalez
Investigator: Simon K. Law, MD
Open Actively Recruiting

Understanding COVID-19 in Patients with Rheumatic Disease

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Tiffany De Leon
Open Actively Recruiting

COVID-19 Questionnaire in UCLA Rheumatoid Arthritis Patients

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Michelle Ramirez
Open Actively Recruiting

Observational Cohort of Hospitalized Patients with COVID-19 at UCLA

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults, Children
Contact: Adreanne Rivera
Open Actively Recruiting

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Sai Sravya Sankar
Open Actively Recruiting

An observational study evaluating viral shedding and development of immune responses in mother-infant pairs affected by COVID-19

The goal of this study is to understand how pregnant women and their newborn babies respond to SARS-CoV-2 infection in pregnancy, the virus responsible for COVID-19. The two main purposes of the study are: 1) to evaluate for the presence of the virus and development of antibodies in pregnant women diagnosed with COVID-19 and their newborn infants over time, and 2) to monitor markers of disease severity in the same blood samples. The research study will last one year. We will collect blood samples from you to check for the presence of antibodies and markers of disease severity at the time of enrollment, at delivery, 6-weeks, 6-months and 12-months. We will collect blood samples from your baby at 24-hours of life (at the hospital, with routine labs), at 6 months, and 12 months. We will also collect nasopharyngeal swabs from you at delivery to detect the presence of virus in your nose, and from your baby within 48 hours of life. We expect you will be in this research study for a total of 4 visits for you and your baby, with each evaluation lasting approximately 30 minutes until 1 year after birth.

Age Group: Adults, Children
Contact: Tara Kerin
Open Actively Recruiting

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.

Phase: Phase 4
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Lorenzo Duvergne
Investigator: George W. Lim, MD
Open Actively Recruiting

Strategies and Treatments for Respiratory Infections &; Viral Emergencies (STRIVE): Shionogi Protease Inhibitor

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd.

The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of S-217622 when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

Phase: Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Julia Vargas
Investigator: George W. Lim, MD
Open Actively Recruiting

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19).

The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

Phase: Phase 2/Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Yun Yong Lei
Open Actively Recruiting

COVID-19 Surveillance in Healthcare Workers and Patients: Observational Studies from the Influenza Vaccine Effectiveness in the Critically Ill (IVY) Network

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Nida Qadir
Investigator: Nida Qadir, MD
Open Actively Recruiting

Covid-19 Critical Care Consortium Incorporating the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMOCARD)

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults, Children
Contact: Jennifer Scovotti
Open Actively Recruiting

COVID Evaluation of Risk for Emergency Departments (COVERED) Project

This CDC sponsored surveillance project is designed to assess risk exposures and COVID-19 infections among working emergency department personnel. The project will require participants to provide ongoing information on risk exposures, and will collect additional information on institutional and community risks. These risk assessments will be combined with assessment of disease status, as determined by serologic testing at two-week intervals. The goal of the project is to identify the most important and potentially correctable risk factors that emergency department personnel face while dealing in with the coronavirus pandemic.

Age Group: Adults
Contact: Julia Vargas
Open Actively Recruiting

Immunological Tolerance in Patients With Mismatched Kidney Transplants

This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: DANA LEVIN-LOPEZ
Investigator:
NEIL KOGUT
Open Actively Recruiting

Mechanical Interventions for Persistent Hypoxemia in Patients Receiving VV ECMO for COVID-19: A Multicenter Retrospective Study

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Jennifer Scovotti
Open Actively Recruiting

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2. All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center (MARC) at University of California Los Angeles (UCLA). This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. The research team will collect self-reported measures of mental health symptoms, physical health symptoms, and demographic information before and after participants attend MAPs. Objective health measures will also be collected by the research team including an active stand test, a 6-minute walk, and a blood sample.

Phase: N/A
Primary Purpose: Supportive care
Gender: Female
Age Group: Adults
Contact: ELIZABETH VANDENBOGAART
Open Actively Recruiting

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).

Phase: Phase 2
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: JENNIFER COWEN
Investigator:
James McCracken
Open Actively Recruiting

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.

Phase: Phase 1/Phase 2
Primary Purpose: Prevention
Gender: All
Age Group: Children
Contact: Michele Carter
Open Actively Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy.

ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult participants will be enrolled in the study across sites worldwide.

In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Efrata Negatu